Atossa Therapeutics (NASDAQ: ATOS)
FY 2023 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED)2023-12-20 | ||||||
REV |
FY 2023 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED)2023-11-09 | ||||||
REV |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|
You can purchase shares of Atossa Therapeutics (NASDAQ: ATOS) through any online brokerage.
Other companies in Atossa Therapeutics’s space includes: Fortress Biotech (NASDAQ:FBIO), Anixa Biosciences (NASDAQ:ANIX), Galectin Therapeutics (NASDAQ:GALT), OncoCyte (NASDAQ:OCX) and Inozyme Pharma (NASDAQ:INZY).
The latest price target for Atossa Therapeutics (NASDAQ: ATOS) was reported by Cantor Fitzgerald on Friday, August 12, 2022. The analyst firm set a price target for 4.00 expecting ATOS to rise to within 12 months (a possible 270.37% upside). 50 analyst firms have reported ratings in the last year.
The stock price for Atossa Therapeutics (NASDAQ: ATOS) is $1.08 last updated August 12, 2022, 8:00 PM UTC.
The next Atossa Therapeutics (ATOS) dividend date is projected to be Thursday, September 1, 2022.
Atossa Therapeutics’s FY earnings are confirmed for Wednesday, December 20, 2023.
There is no upcoming split for Atossa Therapeutics.
Atossa Therapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.